Craft

HanAll BioPharma

Stock Price

₩45.7 K

2024-10-29

Market Capitalization

₩2.3 T

2024-10-29

Revenue

₩155.2 B

FY, 2025

HanAll BioPharma Summary

Company Summary

Overview
HanAll BioPharma (한올바이오파마) is a pharmaceutical company. It offers specialty drugs and over-the-counter products for the treatment of various severe autoimmune diseases, cerebrovascular and peripheral blood vessel disorder, hypertension, atherosclerotic symptom, acute coronary syndrome, etc.
Type
Public
Status
Active
Founded
1973
HQ
Seoul, KR | view all locations
Website
http://en.hanall.co.kr/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

LocationsView all

4 locations detected

  • Seoul, Seoul HQ

    Korea (Republic of)

    Daewoong Building 3F, 12 Bongeunsa-ro 114-gil

  • Daejeon, Daejeon

    Korea (Republic of)

    #208, 2F, Megan Techno World, 199, Techno 2-ro

  • Daejeon, Daejeon

    Korea (Republic of)

    43 Sangseodang 1-gil

  • Suwon, Gyeonggi-do

    Korea (Republic of)

    10th floor, Gyeonggi Bio Center, 147

HanAll BioPharma Financials

Summary Financials

Revenue (FY, 2025)
₩155.2B
Gross profit (FY, 2025)
₩83.9B
Net income (FY, 2025)
(₩5.6B)
Cash (FY, 2025)
₩24.7B
EBIT (FY, 2025)
(₩2.1B)
Enterprise value
$2.3T

Footer menu